Back to top

Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?

Read MoreHide Full Article

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Kamada (KMDA - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.

Kamada is a member of our Medical group, which includes 763 different companies and currently sits at #9 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. KMDA is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for KMDA's full-year earnings has moved 26.98% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Our latest available data shows that KMDA has returned about 7.37% since the start of the calendar year. In comparison, Medical companies have returned an average of -0.59%. This means that Kamada is performing better than its sector in terms of year-to-date returns.

Looking more specifically, KMDA belongs to the Medical - Biomedical and Genetics industry, a group that includes 282 individual stocks and currently sits at #153 in the Zacks Industry Rank. On average, stocks in this group have lost 6.27% this year, meaning that KMDA is performing better in terms of year-to-date returns.

Going forward, investors interested in Medical stocks should continue to pay close attention to KMDA as it looks to continue its solid performance.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Kamada Ltd. (KMDA) - free report >>

More from Zacks Tale of the Tape

You May Like